Rituximab-mediated sensitization of B-non-Hodgkin's lymphoma (NHL) to cytotoxicity induced by paclitaxel, gemcitabine, and vinorelbine

Cancer Biotherapy and Radiopharmaceuticals

Volumn 17, Issue 6, 2002, Pages 621-630

  Emmanouilides, Christos ^a   Jazirehi, Ali R ^a   Bonavida, Benjamin ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Apoptosis; Drug resistance; Non Hodgkin's lymphoma; Sensitization

Indexed keywords

ANTINEOPLASTIC AGENT; CD20 ANTIGEN; FLUDARABINE; GEMCITABINE; IFOSFAMIDE; MITOXANTRONE; MONOCLONAL ANTIBODY; NAVELBINE; PACLITAXEL; PROTEIN BCL 2; RITUXIMAB;

APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CELL CYCLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LYMPHOMA CELL; MULTIDRUG RESISTANCE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; SENSITIZATION;

EID: 0036928350     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/108497802320970226     Document Type: Article

References (47)

1. Chassagne-Clement C, Blay JY, Treilleux I, Sebban C, Bergeron C, Biron P, Philip, I. Epidemiology of non-Hodgkin's lymphoma: Recent data. Bull Cancer 1999;86:529-536.
2. Hauke RJ, Armitage JO. Treatment of non-Hodgkin lymphoma. Curr Opin Oncol 2000;12:412-418.
3. Fisher RI. Diffuse large-cell lymphoma. Ann Oncol 2000;11Suppl 1:29-33.
4. Emmanouilides C. Treatment of indolent lymphoma with fludarabine/mitoxantrone combination: A phase II trial. Hematol Oncol 1998;16:107-116.
5. Rowinsky EK, Donehower RC. Paclitaxel (taxol). N Engl J Med 1995;332:1004-1014.
6. Press OW, LeBlanc M, O'Rourke TJ, Gagnet S, Chapman RA, Balcerzak SP, Fisher, R. I. Phase II trial of paclitaxel by 24-hour continuous infusion for relapsed non-Hodgkin's lymphomas: Southwest Oncology Group trial 9246. J Clin Oncol 1998;16:574-578.
7. Romaguera JE, Rodriguez MA, Hagemeister FB, McLaughlin P, Rodriguez J, Preti A, Younes A, Sarris AH, Cabanilla F. Phase II study of paclitaxel in combination with mitoxantrone and ifosfamide/mesna for patients with relapsed or refractory non-Hodgkin's lymphoma after failure to cytarabine/cisplatin combination. Invest New Drugs 1999;17:187-199.
8. Wilson WH, Chabner BA, Bryant G, Bates S, Fojo A, Regis J, Jaffe ES, Steinberg SM, Goldspiel BR, Cheson BD, et al. Phase II study of paclitaxel in relapsed non-Hodgkin's lymphomas. J Clin Oncol 1995;13:381-386.
9. King K, Younes A. Ifosfamide- and paclitaxel-based treatment of relapsed and refractory lymphoma. Semin Oncol 2000;27:14-22.
10. Younes A, Rodriguez MA, McLaughlin P, North L, Sarris AH, Pate O'Hagemeister FB, Romaguera J, Preti A, Bachier C, Cabanillas F. Phase I study of fludarabine and paclitaxel for the treatment of low-grade non-Hodgkin's lymphoma. Leuk Lymphoma 1997;26:77-82.
11. Haldar S, Basu A, Croce CM. Bcl2 is the guardian of microtubule integrity. Cancer Res 1997;57:29-233.
12. Gazitt Y, Rothenberg ML, Hilsenbeck SG, Fey V, Thomas C, Montegomrey W. Bcl-2 overexpression is associated with resistance to paclitaxel, but not gemcitabine, in multiple myeloma cells. Int J Oncol 1998;13:839-848.
13. Haldar S, Jena N, Croce CM. Antiapoptosis potential of bcl-2 oncogene by dephosphorylation. Biochem Cell Biol 1994;72:455-462.
14. Haldar S, Chintapalli J, Croce CM. Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res 1996;56:1253-1255.
15. Milross CG, Mason KA, Hunter NR, Chung WK, Peters LJ, Milas L. Relationship of mitotic arrest and apoptosis to antitumor effect of paclitaxel. J Natl Cancer Inst 1996;88:1308-1314.
16. Zhou X, Xu L, He K. The role of bcl-2 gene family in taxol-mediated apoptosis in BJAB B cell lymphoma cell line. Zhonghua Zhong Liu Za Zhi 2000;22:453-455.
17. Barton-Burke M. Gemcitabine: A pharmacologic and clinical overview. Cancer Nurs 1999;22:176-183.
18. Savage DG, Rule SA, Tighe M, Garrett TJ, Oster MW, Lee RT, et al. Gemcitabine for relapsed or resistant lymphoma. Ann Oncol 2000;11:595-597.
19. Nabhan C, Krett N, Gandhi V, Rosen S. Gemcitabine in hematologic malignancies. Curr Opin Oncol 2001;13:514-521.
20. Dumontet C, Morschhauser F, Solal-Celigny P, Bouafia F, Bourgeois E, Thieblemont C, Leleu, X., Hequet, O, Salles G, Coiffier B. Gemcitabine as a single agent in the treatment of relapsed or refractory low-grade non-Hodgkin's lymphoma. Br J Haematol 2001;113:772-778.
21. Gregory RK, Smith IE. Vinorelbine - A clinical review. Br J Cancer 2000;82:1907-1913.
22. Balzarotti M, Santoro A, Tondini C, Fornier M, Bonadonna G. Activity of single agent vinorelbine in pretreated non-Hodgkin's lymphoma. Ann Oncol 1996;7:970-972.
23. Coiffier B, Haioun C, Ketterer N, Engert A, Tilly H, Ma D, Johnson P, Lister A, Feuring-Buske M, Radford JA, Capdeville R, Diel V, Reyes F. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study. Blood 1998;92:1927-1932.
24. McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Buckler I, White CA, Jain V, Ho AD, Lister J, Wey K, Shen D, Dallair BK. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol 1998;16:2825-2833.
25. Emmanouilides C, Rosen P, Telatar M, Malone R, Bosserman L, Menco H, Patel R, Barstis J, Grody W.W. Excellent tolerance of rituxan when administered after cyclophosphamide-mitoxantrone. An effective regimen in NHL. Clin Lymphoma 2000;1:146-151.
26. Czuczman MS, Grillo-Lopez AJ, White CA, Saleh M, Gordon L, LoBuglio AF, Janas C, Klippenstein D, Dallaire B, Varns C. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999;17:268-276.
27. Emmanouilides C. Treatment of indolent lymphoma with fludarabine/mitoxantrone combination: A phase II trial. Hematol Oncol 1998;16:107-116.
28. Vose JM, Link BK, Grossbard ML, Czuczman M, Grillo-Lopez A, Gilman P, Lowe A, Kunkel LA, Fisher RI. Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. J Clin Oncol 2001;19:389-397.
29. Demidem A, Lam T, Alas S, Hariharan K, Hanna N, Bonavida B. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm 1997;12:177-186.
30. Alas S, Bonavida B, Emmanouilides C. Potentiation of fludarabine cytotoxicity on non-Hodgkin's lymphoma by pentoxifylline and rituximab. Anticancer Res 2000;20:2961-2966.
31. Alas S, Emmanouilides C, Bonavida B. Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis. Clin Cancer Res 2001;7:709-723.
32. Klein E, Klein G, Mandarin JS, Mandarin JJ, Wigell H, Clifford P. Surface IgM-k specificity on a Burkett lymphoma cell in vivo and in derived culture lines. Cancer Res 1968;28:1300-1310.
33. Klein G, Giovanella B, Westman A, Stehlin JS, Mumford D. An EBV-genome-negative cell line established from an American Burkitt's lymphoma; receptor characteristics. EBV infectibility and permanent conversion into EBV-positive sublines by in vitro infection. Intervirology 1975;5:319-334.
34. Ng VL, Hurt MH, Fein CL, Khayam-Bashi F, Marsh J, Nunes WM, McPhaul LW, Feigal E, Nelson P, Herndier BG, Shiramizu B, Reyes GR, Fry KE, McGrath MS. IgMs produced by two acquired immune deficiency syndrome lymphoma cell lines: Ig binding specificity and VH-gene putative somatic mutation analysis. Blood 1994;83:1067-1078.
35. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Meth 1991;139:271-279.
36. Maloney DG, Smith B, Applebaum FR. The anti-tumor effect of monoclonal anti-CD20 antibody (mAB) therapy includes direct anti-proliferative activity and induction of apoptosis in CD20 positive non-Hodgkin's lymphoma (NHL) cell lines. Blood 1996;88:637a.
37. Anderson DR, Grillo-Lopez A, Varns C, Chambers KS, Hanna N. Targeted anti-cancer therapy using rituximab, a chimeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma. Biochem Soc Trans 1997;25:705-708.
38. Berinstein NL, Grillo-Lopez AJ, White CA, Bence-Bruckler I, Maloney D, Czuczman M, Green D, Rosenberg J, McLaughlin P, Shen D. Association of serum rituximab (IDEC-C2B8) concentration and antitumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 1998;9:995-1001.
39. Fan W. Possible mechanisms of paclitaxel-induced apoptosis. Biochem Pharmacol 1999;57:1215.
40. Younes A, Romaguera J, Mesina O, Hagemeister F, Sarris AH, Rodriguez MA, McLaughlin P, Preti HA, Bachier C, Cabanillas G. Paclitaxel plus high-dose cyclophosphamide with G-CSF support in patients with relapsed and refractory aggressive non-Hodgkin's lymphoma. Br J Haematol 1998;103:678-683.
41. Miller TP, Chase EM, Dorr R, Dalton WS, Lam KS, Salmon SE. A phase I/II trial of paclitaxel for non-Hodgkin's lymphoma followed by paclitaxel plus quinine in drug-resistant disease. Anticancer Drugs 1998;9:135-140.
42. Maloney D, Smith B, Rose A. Rituximab: Mechanism of action and resistance. Sem Oncol 2002;29:2-9.
43. Hofmeister JK, Cooney D, Coggeshall KM. Clustered CD20 induced apoptosis: Src-family kinase, the proximal regulator of tyrosine phosphorylation, calcium influx, and caspase 3-dependent apoptosis. Blood Cells Mol Dis 2000;26:133-143.
44. Mathas S, Rickers A, Bommert K, Dorken B, Mapara MY. Anti-CD20 and B-cell receptor-mediated apoptosis: Evidence for shared intracellular signaling pathways. Cancer Res 2000;60:7170-7176.
45. Jazirehi AR, Gan X-H, De Vos S, Bonavida B, Emmanouilides C. Rituximab (anti-CD20) selectively down-regulates Bcl-xL and up-regulates Apaf-1 in Non-Hodgkin's Lymphoma (NHL) B-cells: Complementation with Paclitaxel results in synergy in apoptosis. (2002, submitted, Journal of Immunology).
46. Physician's Desk Reference. Taxol monograph: 1129-1137, Navelbine monograph: 1604-1607, Gemcitabine monograph: 1919-1924, Medical Economics Company, Inc., Montale, NJ. (2002).
47. Emmanouilides C, Territo M, Malone R, et al. Rituxan and vinorelbine combination is active in the treatment of NHL relapsing posttransplant. Blood 2000;96:237b.